Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2927 · 2 trials · 2 indications
Change in LAERP from before IP infusion to 1st and 2nd assessments during IP infusion
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | A single dose of AZD2927 administered as an iv infusion |
| 2 | PLACEBO_COMPARATOR | A single dose of placebo administered as an iv infusion |
| Name | Type | Description |
|---|---|---|
| AZD2927 | DRUG | A single dose of AZD2927 administered as an iv infusion |
| Placebo | DRUG | A single dose of placebo administered as an iv infusion |
Inclusion Criteria: * male or postmenopausal female, aged 20 to 80 years inclusive, * clinical indication for catheter ablation of atrial flutter, * history of paroxysmal atrial flutter, with or without paroxysmal AF. Single episodes of persistent atrial flutter or AF requiring cardioversion do not...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Abbott Laboratories | ABT | 5 | - | Undisclosed |
| Medtronic Plc | MDT | 1 | - | Undisclosed |
| Boston Scientific Corporation | BSX | 1 | - | Undisclosed |
| HeartBeam, Inc. | BEAT | 1 | - | Undisclosed |
| Cardio Diagnostics Holdings Inc. | CDIO | 1 | - | Undisclosed |
AZD2927 is an investigational small molecule being studied for cardiovascular conditions, specifically arrhythmia. It has also been evaluated in healthy volunteers to assess its safety and pharmacological effects. The drug is currently in Phase 2 clinical development and is not approved by regulatory authorities.
AZD2927 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in cardiovascular indications.
AZD2927 is in Phase 2 clinical development. It has completed a Phase 1 study in healthy volunteers and a Phase 2 study in patients with arrhythmia. The drug remains investigational and has not received regulatory approval for any indication.
AZD2927 has been studied in two completed clinical trials. NCT01264250 was a Phase 1 study in healthy male volunteers in Sweden, and NCT01396226 was a Phase 2 study comparing AZD2927 to placebo in patients with arrhythmia in Norway and Sweden.
AZD2927 is a unique investigational compound developed by AstraZeneca. No alternative names or brand names have been associated with this drug in clinical development. It is identified solely by its code name AZD2927 in scientific literature and trial registries.